Literature DB >> 7586059

Structure-activity relationships of neuromedin U. II. Highly potent analogs substituted or modified at the N-terminus of neuromedin U-8.

T Hashimoto1, K Kurosawa, N Sakura.   

Abstract

To develop a highly potent agonist and to examine the structure-contractile activity relationship of neuromedin U-8(NMU-8), seventeen analogs were synthesized and tested for contractile activity on isolated chicken crop smooth muscle preparations. The analogs were designed to examine the contributions of cyclic structure and acidic function at the N-terminal of NMU-8 and NMU-8(2--8) to the biological activity. The relative activity (RA) values of NMU-8 analogs were as follows: [Dp-Glu1]-NMU-8,5.50; [pyrohomoglutamyl(pHgu)1]-NMU-8,4.65;[D-pHgu1]-NMU-8, 4.66; [Asp1]-NMU-8, 11.4; [acetyl(Ac)-Asp1]-NMU-8, 9.81; [Ac-Glu1]- NMU-8, 18.6; [succinyl (Suc)-Tyr1-NMU-8,69.3; [3-sulfoalanyl (Sal)1]-NMU-8, 12.7. The RA values of NMU-8(2--8) analogs were as follows: alpha-picolinyl (Pic)-NMU-8 (2--8), 7.96; 2-furoyl (Fur)-NMU-8, (2--8), 9.91; 2-thiophenecarboxyl (Thi)-NMU-8 (2--8), 3.41; 4-hydroxyphenylpropionyl (Hpp)-NMU-8(2--8), 3.20; o-phthalyl (Pht)-NMU-8 (2--8), 11.3; Suc-NMU-8 (2--8), 109; malonyl (Mlo)-NMU-8 (2--8), 17.9; maleyl (Mle)-NMU-8 (2--8), 31.6; glutaryl (Glt)-NMU-8 (2--8), 81.3; The potencies of the analogs were higher than that of p-NMU-8. Suc-NMU-8 (2--8) showed the highest potency among the analogs synthesized. The results reveal that the carboxylic acid group at the N-terminus of NMU-8 makes a major contribution to the activity.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7586059     DOI: 10.1248/cpb.43.1154

Source DB:  PubMed          Journal:  Chem Pharm Bull (Tokyo)        ISSN: 0009-2363            Impact factor:   1.645


  5 in total

1.  Discovery of potent hexapeptide agonists to human neuromedin u receptor 1 and identification of their serum metabolites.

Authors:  Kentaro Takayama; Kenji Mori; Yuko Sohma; Koji Taketa; Akihiro Taguchi; Fumika Yakushiji; Naoto Minamino; Mikiya Miyazato; Kenji Kangawa; Yoshio Hayashi
Journal:  ACS Med Chem Lett       Date:  2015-01-28       Impact factor: 4.345

2.  Small lipidated anti-obesity compounds derived from neuromedin U.

Authors:  Ewa D Micewicz; Omar S O Bahattab; Gary B Willars; Alan J Waring; Mohamad Navab; Julian P Whitelegge; William H McBride; Piotr Ruchala
Journal:  Eur J Med Chem       Date:  2015-07-14       Impact factor: 6.514

3.  The role of neuromedin U in adiposity regulation. Haplotype analysis in European children from the IDEFICS Cohort.

Authors:  Francesco Gianfagna; Claudio Grippi; Wolfgang Ahrens; Mark E S Bailey; Claudia Börnhorst; Stefan De Henauw; Ronja Foraita; Anna C Koni; Vittorio Krogh; Staffan Mårild; Dénes Molnár; Luis Moreno; Yannis Pitsiladis; Paola Russo; Alfonso Siani; Michael Tornaritis; Toomas Veidebaum; Licia Iacoviello
Journal:  PLoS One       Date:  2017-02-24       Impact factor: 3.240

4.  Neuromedin U induces an invasive phenotype in CRC cells expressing the NMUR2 receptor.

Authors:  Patrycja Przygodzka; Ewelina Sochacka; Kamila Soboska; Marcin Pacholczyk; Izabela Papiewska-Pająk; Tomasz Przygodzki; Przemysław Płociński; Steven Ballet; An De Prins; Joanna Boncela
Journal:  J Exp Clin Cancer Res       Date:  2021-09-07

5.  Negative regulation of neuromedin U mRNA expression in the rat pars tuberalis by melatonin.

Authors:  Sayaka Aizawa; Ichiro Sakata; Mai Nagasaka; Yuriko Higaki; Takafumi Sakai
Journal:  PLoS One       Date:  2013-07-02       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.